Heney D, Lewis I J, Ghoneim A T, Chisholm P, Bailey C C
Department of Paediatrics, St James's University Hospital, Leeds, UK.
J Antimicrob Chemother. 1991 Jul;28(1):117-29. doi: 10.1093/jac/28.1.117.
In a prospective, randomized trial in 100 febrile neutropenic children, aztreonam plus flucloxacillin was compared with piperacillin plus gentamicin. At the 72 h clinical assessment there was no statistically significant difference between the two groups. However, in microbiologically documented infections there was a higher response rate in the piperacillin/gentamicin group (57%) than in the aztreonam/flucoxacillin group (41%). This was contributed to by the poorer Gram-positive cover of the aztreonam/flucloxacillin combination. In clinically documented infections and unexplained fevers the response rate of the two antibiotic regimens was identical. There were two deaths; one early death (in the piperacillin/gentamicin arm) and one late death. At the final assessment a successful outcome was obtained in the remaining patients. In the aztreonam/flucloxacillin group 75% of the episodes required modification compared with 59% in the piperacillin/gentamicin group.
在一项针对100名发热性中性粒细胞减少儿童的前瞻性随机试验中，将氨曲南加氟氯西林与哌拉西林加庆大霉素进行了比较。在72小时临床评估时，两组之间无统计学显著差异。然而，在微生物学确诊的感染中，哌拉西林/庆大霉素组的缓解率（57%）高于氨曲南/氟氯西林组（41%）。这是由于氨曲南/氟氯西林组合对革兰氏阳性菌的覆盖较差所致。在临床确诊的感染和不明原因发热中，两种抗生素治疗方案的缓解率相同。有两例死亡；一例早期死亡（在哌拉西林/庆大霉素组）和一例晚期死亡。在最终评估时，其余患者均获得了成功的治疗结果。氨曲南/氟氯西林组75%的病例需要调整治疗方案，而哌拉西林/庆大霉素组为59%。
